• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Immunol . One Action and Multiple Results: Influenza A Virus and SARS-CoV-2 Poly-Epitope-Based Hybrid Vaccine Exploration by Reverse Vaccinology

tetano

Editor, Senior Moderator
Hum Immunol


. 2025 Oct 4;86(6):111588.
doi: 10.1016/j.humimm.2025.111588. Online ahead of print. One Action and Multiple Results: Influenza A Virus and SARS-CoV-2 Poly-Epitope-Based Hybrid Vaccine Exploration by Reverse Vaccinology and Immunoinformatic Methods

Fatemeh Razmjooei[SUP] 1 [/SUP], Mohammad Izadi[SUP] 2 [/SUP], Abbas Dehghanian[SUP] 3 [/SUP], Sina Hassani[SUP] 4 [/SUP], Hamed Mir[SUP] 4 [/SUP], Mirza Ali Mofazzal Jahromi[SUP] 5 [/SUP], Mohammad Aref Bagherzadeh[SUP] 6 [/SUP]



Affiliations
Abstract

Introduction: Influenza A virus (IAV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coinfection have been shown to intensify symptoms and, therefore, could be considered a significant threat to susceptible populations. Although vaccination is an effective and safe strategy to be used against viruses, large amounts of mutations in these two viruses remain an issue for vaccine design, as some strains of the IAV and SARS-CoV-2 are still present worldwide, regardless of the introduction of various vaccines to protect against the viruses.
Methods: We employed a bioinformatic approach to design a hybrid vaccine based on the epitopes of IAV and SARS-CoV-2, which are potentially conserved against mutations and are safe in terms of toxicity and allergenicity, yet promise to induce long-lasting innate and adaptive immune responses.
Results: The selected peptides demonstrated a potentially effective immune response and showed promise as safe and suitable for hybrid vaccine design. We selected epitopes focusing on their binding quality to cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B cell. For instance, CTL's epitopes were checked using sequence-based prediction methods, and their entropy and antigenicity were confirmed. Similarly, all epitopes were selected based on their ability to induce robust humoral and cell-mediated immunity, respectively.
Conclusion: Hybrid vaccine design, utilizing our approach, can lead to next-generation hybrid vaccines that help the healthcare system establish a more consistent defense against both viruses for the susceptible population.

Keywords: Conserved epitopes; Hybrid vaccine; Immunoinformatics; Influenza A virus; Reverse vaccinology; SARS-CoV-2.

 
Back
Top Bottom